Tag Archives | precision medicine

Biotech Weakness but why Large Caps?…Updates

source Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

IBB Hits 2018 High but FBT is Still the Leading ETF over 5 Years: CAR-T, RNAi …Updates

buy cephalon modafinil 8/30/18 Weak Rally to another Round of Highs Curbed by more Tough Tariff Threats This week’s rally and uber bullish sentiment was slowed by Tough Talk about $200B in new tariffs next week. Other news from Trump on Google, Facebook and Amazon threatening antitrust action curbed buyers at mid-day. FBT to $157.43 at new highs […]

Continue Reading 0

Biotech Snapshot: Healthcare Sector Remains Strong-Updates

enter 8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500, Russell 2000, NASDAQ Composite IBB at $117.40 pushing toward 2018 FEB […]

Continue Reading 0

Biotech Snapshot During a Rally Day: No Summer Doldrums…Updates

Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%,  XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]

Continue Reading 0

Rayno Biopharma Portfolio 2018 YTD: Performance Summary

9/10 Update: Long Tesaro (TSRO) We added small positions at $32 on August 21 and more on 9/7 at $35+. =============== Rayno Biopharma Performance 2018: YTD 8/4 Large Caps Begin to Outperform FBT Is the Best All Around Life Science Play up 19% YTD We have provided herein a summary of biopharma portfolio positions for […]

Continue Reading 0

Mid-Cap Biotech Watch List: Updated 6/12/18 After Huge ASCO Rally

  Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of the best ASCO stock rallies on record in 2018 focusing on small and […]

Continue Reading 0

ASCO 2018 Biotech Rally Part 2 : Traders Take Profits on Nice Gains…Updates

ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD,  IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum easing from profit taking and digestion of news. […]

Continue Reading 0

ASCO 2018 Biotech Rally : Teetering at the Top But a Leading Sector

ASCO 2018 Biotech Rally: Biotechs, Techs, and Semis Lead Market Higher Mid-Caps show huge gains but with high volatility. FBT at 142.91, IBB lagging at $110.52, XBI leading at $97.77 IWC Micro-Cap ETF breaking out up 11% YTD. Healthcare (XLV) comes to life lately up over 2% YTD. As we predicted in early May Mid-Cap […]

Continue Reading 0

Financial and Political Crisis in Italy Disrupts Biotech Stock Momentum…Updates with rally today 5/30

Updates 5/30 Pre-ASCO Rally: XBI regains momentum to $94 level. IBB breaks through SMA 200 level to $108+. Many mid-caps from our watch list soaring-CRSP*, FMI, FOLD, LGND, LOXO, NKTR, SGEN, SRPT etc. *Note CRSP got whacked after hours down 13 points! The FDA has put the clinical trial for sickle cell treatment on hold. […]

Continue Reading 0

Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9

Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]

Continue Reading 0